Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1, kappa|
|Storage buffer||PBS with sucrose, BSA|
|Contains||0.1% sodium azide|
|Storage Conditions||4° C, store in dark|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||Assay-Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Flow Cytometry (Flow)||See 2 publications below|
R-phycoerythrin (PE) is a stable and highly soluble phycobiliprotein which provides maximal absorbance and fluorescence without susceptibility to internal or external fluorescence quenching, thus providing an exceptional quantum yields and molar extinction coefficients.
This gene encodes a receptor for the Fc portion of immunoglobulin G, and it is involved in the removal of antigen-antibody complexes from the circulation, as well as other other antibody-dependent responses. This gene (FCGR3A) is highly similar to another nearby gene (FCGR3B) located on chromosome 1. The receptor encoded by this gene is expressed on natural killer (NK) cells as an integral membrane glycoprotein anchored through a transmembrane peptide, whereas FCGR3B is expressed on polymorphonuclear neutrophils (PMN) where the receptor is anchored through a phosphatidylinositol (PI) linkage. Mutations in this gene have been linked to susceptibility to recurrent viral infections, susceptibility to systemic lupus erythematosus, and alloimmune neonatal neutropenia. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.
Analyte Specific Reagent
Biochemical and pharmacological characterization of AZD1981, an orally available selective DP2 antagonist in clinical development for asthma.
MHCD1604-4 was used in flow cytometry to identify and characterize a novel DP2 receptor antagonist.
|Schmidt JA,Bell FM,Akam E,Marshall C,Dainty IA,Heinemann A,Dougall IG,Bonnert RV,Sargent CA||British journal of pharmacology (168:1626)||2013|
Perturbations in eosinophil homeostasis following treatment of lymphatic filariasis.
MHCD1604-4 was used in flow cytometry to study perturbations in eosinophil homeostasis following treatment of lymphatic filariasis.
|Gopinath R,Hanna LE,Kumaraswami V,Perumal V,Kavitha V,Vijayasekaran V,Nutman TB||Infection and immunity (68:93)||2000|
CD16A; CD16a antigen; CD16B; Fc fragment of IgG low affinity IIIa receptor; Fc fragment of IgG, low affinity III, receptor for (CD16); Fc fragment of IgG, low affinity IIIa, receptor (CD16a); Fc fragment of IgG, low affinity IIIb, receptor (CD16b); Fc gamma Receptor 3; Fc gamma Receptor III; Fc gamma receptor III-A; Fc gamma receptor IIIa; Fc gamma receptor IIIb; Fc-gamma receptor III-2 (CD 16); Fc-gamma receptor IIIb (CD 16); Fc-gamma receptor IIIb (CD16); fc-gamma RIII; Fc-gamma RIII-alpha; fc-gamma RIII-beta; Fc-gamma RIIIa; fc-gamma RIIIb; FcgammaRIIIA; FCGR3; FCGR3A; FCGR3B; FCGRIII; FCR-10; FCRIII; FCRIIIA; igG Fc receptor III-1; igG Fc receptor III-2; immunoglobulin G Fc receptor III; neutrophil-specific antigen NA; RP11-5K23.1
CD16; CD16A; CD16B; FCG3; FCGR3; FCGR3A; FCGR3B; FCGRIII; FCR-10; FCRIII; FCRIIIA; FCRIIIb; IGFR3; IMD20